Tris Pharma Reports Positive Phase 3 Results for Cebranopadol in Acute Pain Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company dedicated to developing innovative pain management therapies, has announced positive topline results from its ALLEVIATE-2 Phase 3 pivotal clinical trial…
NeuPath Health Launches Arthrosamid® for Knee Osteoarthritis NeuPath Health Inc. (TSXV: NPTH) (“NeuPath” or the “Company”), a leading provider of chronic pain treatment through its extensive network of clinics, has achieved a groundbreaking milestone in North America. The company proudly…
Parse Biosciences Progresses Towards Launching Single-Cell Chromatin Accessibility Products Parse Biosciences, a leading innovator in scalable and accessible single-cell sequencing technology, has reaffirmed its commitment to advancing its Evercode™ single-cell chromatin accessibility products. This announcement marks a significant milestone for…
Gensaic Partners with Novo Nordisk to Advance Next-Gen Precision Therapies Gensaic, Inc., a pioneering biotechnology company leveraging AI-driven protein design and biological insights to develop precision ligands for targeted drug delivery, has announced a major discovery and license collaboration with…
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, has unveiled promising preclinical data on SOT109, a next-generation antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17). These findings reinforce the strong therapeutic potential of SOT109 in treating colorectal cancer (CRC) and…
Revvity’s EUROIMMUN Secures CE Mark for Innovative Measles Antibody Test Revvity, Inc. (NYSE: RVTY) has announced the launch of EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG), which has received the CE mark. This novel assay is designed to support both the…
LabVantage Solutions Unveils LIMS 8.9: Transforming Lab Productivity and Efficiency LabVantage Solutions, Inc., a global leader in laboratory informatics, has announced the launch of LabVantage 8.9, the latest evolution of its cutting-edge Laboratory Information Management System (LIMS). This new release…
Protagonist and Takeda Announce Positive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ: PTGX) and Takeda (TSE: 4502/NYSE: TAK) have announced positive topline results from the Phase 3 VERIFY study, evaluating rusfertide in…
QIAGEN Takes Legal Action to Defend QuantiFERON Intellectual Property and Protect Innovations in Latent Tuberculosis Testing QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has filed a patent infringement complaint against bioMérieux S.A. (EPA: BIM), reinforcing its commitment to protecting…
Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases Seismic Therapeutic, Inc., a pioneering machine learning immunology company, has announced the presentation of preclinical data for its novel immunoglobulin E (IgE) protease, S-8484. The data reveal S-8484’s ability to…
Astria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema Astria Therapeutics, Inc. (Nasdaq: ATXS), a leading biopharmaceutical company dedicated to developing innovative therapies for allergic and immunological diseases, has officially launched the Phase 3 ALPHA-ORBIT clinical trial of…
Immune-Onc Therapeutics Doses First Patient with IO-108 in Global Phase 1b/2 Liver Cancer Study in Collaboration with Roche Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage biopharmaceutical company focused on developing innovative therapies in immunology and oncology, has announced a significant…